Provided by Tiger Trade Technology Pte. Ltd.

Relay Therapeutics

18.05
-0.3100-1.69%
Post-market: 18.650.6000+3.32%19:37 EDT
Volume:2.78M
Turnover:50.45M
Market Cap:3.96B
PE:-11.53
High:18.72
Open:18.39
Low:17.93
Close:18.36
52wk High:21.27
52wk Low:5.17
Shares:219.14M
Float Shares:145.00M
Volume Ratio:0.83
T/O Rate:1.92%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.5651
EPS(LYR):-1.6113
ROE:-36.77%
ROA:-22.88%
PB:4.44
PE(LYR):-11.20

Loading ...

BUZZ-U.S. STOCKS ON THE MOVE-Nvidia, SiTime Corp, Hoth Therapeutics

Reuters
·
May 19

Relay Therapeutics up 11% in pre-market after zovegalisib update

TIPRANKS
·
May 19

BUZZ-U.S. STOCKS ON THE MOVE-Alphabet, Relay Therapeutics, Amer Sports

Reuters
·
May 19

Relay Therapeutics Says 60% of Patients Responded in Rare Vascular Disorder Drug Study

MT Newswires Live
·
May 19

BUZZ-Relay Therapeutics rises after vascular disorder drug shows promise in study

Reuters
·
May 19

Relay Therapeutics Shares up 7.5% Premarket After Co's Drug Shrinks Vascular Malformations in Mid-Stage Trial

THOMSON REUTERS
·
May 19

Relay Therapeutics’ zovegalisib shows potential efficacy in vascular anomalies

TIPRANKS
·
May 19

Relay Therapeutics reports 60% response rate in Phase 2 zovegalisib vascular anomalies trial

Reuters
·
May 19

Relay Therapeutics Inc - 89% Investigator-Reported and 79% Patient-Reported Clinical Improvement at Week 12

THOMSON REUTERS
·
May 19

Relay Therapeutics Announces Initial Clinical Data Demonstrating That Zovegalisib Has Potential for Differentiated Safety and Efficacy in Patients With Pik3CA-Driven Vascular Anomalies

THOMSON REUTERS
·
May 19

Relay Therapeutics Inc - No Patients Discontinued Treatment Due to Adverse Events

THOMSON REUTERS
·
May 19

Relay Therapeutics Inc - 60% of Patients Achieve Volumetric Response at 12 Weeks as of April 15, 2026

THOMSON REUTERS
·
May 19

Relay Therapeutics Announces Initial Clinical Data Demonstrating That Zovegalisib Has Potential for Differentiated Safety and Efficacy in Patients with PIK3CA-Driven Vascular Anomalies

GlobeNewswire
·
May 19

Relay's treatment shown to shrink vascular malformations in mid-stage trial

Reuters
·
May 19

Relay CFO Thomas Catinazzo sells 17,717 shares for $227,810.62

Reuters
·
May 15

How Relay’s Phase 3 Zovegalisib Breast Cancer Push Could Reshape Relay Therapeutics’ (RLAY) Investment Story

Simply Wall St.
·
May 12

Stock Track | Relay Therapeutics Plummets 6.15% Intraday Following Q1 Earnings Miss and Revenue Decline

Stock Track
·
May 06

Relay Therapeutics (RLAY) Receives a Buy from Oppenheimer

TIPRANKS
·
May 06

Guggenheim Sticks to Their Buy Rating for Relay Therapeutics (RLAY)

TIPRANKS
·
May 06

Stock Track | Relay Therapeutics Plunges 7.69% Post-Market on Q1 EPS Miss and Sharp Revenue Decline

Stock Track
·
May 06